Replies to post #19363 on OWC Pharmaceutical Research Corp (OWCP)

[High_Profits]

***MUST SEE OWCP Videos & Social Media UPDATED***

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=126157756

[High_Profits]

medical Marijuana Conference.. great video

[High_Profits]

Report on Israel Cannabis Industry
https://www.facebook.com/CannaTech2015/videos/1578369659142955/

[High_Profits]

Cannabis COWEN EVENT Take-Aways JEFF FRIEDLAND MENTIONED

http://tinyurl.com/h3sabku

The Cowen Insight

Last week, we hosted our Inaugural Cannabis Colloquium, featuring various speakers covering topics ranging from U.S. policy, consumer trends and investment considerations, to a deep dive into the Canadian cannabis market and the public companies looking to capitalize on the country’s transition to adult use (which we estimate to be a CAD $4 bn in year 1).

Policy: Needs to Play Out

We heard from several policy experts and industry thought leaders, including Ethan Nadelmann (Founder and Executive Director of the Drug Policy Alliance), Allen St. Pierre (former Executive Director of NORML), Jeffrey Friedland (CEO of INTIVA Inc.) and Michael Safir (Business Manager at High Times Magazine). In the U.S., the Trump administration presents uncertainty for the industry, in particular given Trump’s nomination of Jeff Sessions for Attorney General. Broadly, the hope is that cannabis is low on the list of priorities for the administration (in particular given popular support for cannabis legalization, as evidenced by the election outcomes). States that have adopted legal cannabis (either for medical or adult use) will be critical in defending the changes that have already gone into effect (as evidenced by CA’s having hired former AG, Eric Holder). With more states expected to implement an adult use framework in 2018 (and Canada), state legislatures in New England could be motivated to legalize adult use as well, as the benefits of cannabis-related tax revenues in the region become increasingly apparent.

U.S. Market: Fast Growing and Evolving
While the political landscape leaves uncertainty around the evolution of the cannabis market in the U.S., the existing market continues to experience torrid growth, as noted by Cy Scott, the Co-Founder and CEO of Headset, with Washington up 180% in 2016, while CO cannabis sales grew 130%. With an average consumer age of 37, category spend is inline with our estimates, as over 30% of consumers spend in excess of $1,000/year. While flower continues to dominate the market (65% of sales), novel form factors are showing outsized growth. Off of a small base, topicals grew ~400%, which rapid growth was reflected in the insights from Lynn Honderd, Co-Founder of Mary’s Medicinals. Edibles, which account for ~6% of the market, have also experienced rapid growth (over 100%), allowing new market entrant Coda Signature to quickly reach distribution in over 150 dispensaries and become cash flow positive, as articulated by Co-Founder and CEO, Mark Grindeland. In vapor, one of the biggest novel sub-segments (8% of sales), consumers are embracing technology, and are utilizing loose leaf solutions (with tobacco capabilities) for a non-combustion experience. Indeed, Tyler Goldman, CEO of PAX Labs, noted that the company has sold over 1 mm units of their premium priced vaporizer ($280) in just a few years.


The robust growth seen in existing markets, and the notable new market opportunities following the election, continues to fuel interest from new entrants. Both Ben Kaanta, Director of Operations for MJardin, and Brett Roper, COO, Medicine Man Technologies, noted that setting expectations around start-up costs for cultivation operations ($4-$10 mm), market sizing and regulatory complexity filters out a majority of potential clients for their grow consulting services. That said, the nuanced regulatory frameworks adopted by individual states provides a key opportunity for Nick Kovacevich, CEO of Kush Bottles, and the company’s child resistant, compliant packaging. Ultimately, all of these efforts support the dispensary retail model, as noted by President of Medicine Man, Sally Vander Veer, whose chain of dispensaries in CO continue to experience healthy growth (in part fueled by tourism, as the company’s Denver outpost generates 70% of sales from out-of-state visitors).

The Global Cannabis Opportunity, Led by Canada
Brendan Kennedy, Co-Founder and CEO of Privateer Holdings, estimates that the global cannabis market generates sales of ~$200 bn. In addition to Leafly and Marley Natural, the company owns Tilray, a Canadian licensed producer, which has expanded its reach beyond the U.S. via exports to Australia, Latin America and New Zealand. Several other Canadian LP’s have their sights set on the global opportunity as well. Canopy Growth CEO Bruce Linton noted his company is already exporting to Germany and Brazil, while CEO of The Cronus Group, Mike Gorenstein is also exporting to Germany. While both companies are well positioned to capitalize on adult use, which is generally expected in 2018, Dennis Arsenault, CEO of Organigram, noted that his company would remain domestically-focused, given the sizeable opportunity seen for Canada. Consumer research from Deloitte Canada, as presented by Vice Chair and Global Leader for Deloitte Private, Mark Whitmore, supports a focus on Canada as they estimate 22% of adults in the U.S. use cannabis (with another 17% indicating a willingness to try cannabis once legalized).

Vivien Azer
646.562.1351
[e-mail]

Aaron Grey, CFA
646.562.1421
[e-mail]

[High_Profits]

OWCP's MIRAIAM SANI CEO at Shefa Amirim Med Ltd.
http://www.gilsc.org/about-us/the-team/

REGARDING GERMANY Medical Marijuana Legalization
http://www.cnn.com/2016/12/29/health/global-marijuana-cannabis-laws/index.html

GERMANY-ISRAELI LIFE SCIENCES COMMITTEE MEMBERS

Miri Sani has more than 20 years of experience in the Israeli Biotech industry and has worked in several companies as VP of regulatory affairs. As part of her responsibilities, Ms. Sani has designed and conducted many clinical studies. She also led the process of the FDA and CE mark approvals. Ms. Sani served as VP of Regulatory Affairs in Notal Vision that developed solutions for the early detection and monitoring of Age-Related Macular Degeneration (AMD), ConTipi that provided female urine incontinence solutions, and MTRE that developed a thermoregulation system for surgeries. In addition, Ms. Sani is a CEO of a consulting company, Shefa Amirim Med, which has designed and conducted clinical studies for Israeli, incubator-based companies all over the world. In addition, she serves a a regulatory director in several Israeli biotech companies

[High_Profits]

** NEW $OWCP FEB 13th 1 Pg PDF **OWCP
Overview to Download and share
http://tinyurl.com/hko3qzb

** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months

Follow OWCP on Twitter
https://twitter.com/OWCPharma

Follow OWCP on Instagram
https://www.instagram.com/owcpharma/

Like OWCP on Facebook
https://www.facebook.com/OWCpharma/

$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/

OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku

INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true

[High_Profits]

Follow $OWCP on Twitter Now
https://twitter.com/OWCPharma

UPDATED March 17th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/hrsgjyb

Like OWCP on Facebook
https://www.facebook.com/OWCpharma/

** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months

$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/

OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku

INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true

[High_Profits]

Follow $OWCP on Twitter
https://twitter.com/OWCPharma

UPDATED March 25th $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/k8aser4

Like OWCP on Facebook
https://www.facebook.com/OWCpharma/

** NEW $OWCP Seeking Alpha Article **
http://seekingalpha.com/instablog/48086678-lawrencelien/4956399-owc-fire-1200-percent-gain-4-months

$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/

OWCP JPEG Image to Download to your smartphone and share w friends and family
http://tinyurl.com/z29oxku

INCREDIBLE Marijuana Top Stocks VIDEO - OWCP Mentioned
http://pro.moneymappress.com/NVXMJ39TMRSHMPF/PNVXT138/?iris=609989&ad=zb1-tmbmsr-gwl&test_id=1483732928584&_ga=1.214560469.356532129.1483741600&h=true

[High_Profits]

http://www.cannabisfn.com/mdc/one-world-cannabis-ltd/

[High_Profits]

$OWCP Marijuana industry could be worth $50 billion annually by 2026 http://on.mktw.net/2ouR7yL

#MedicalMarijuana #MedicalCannabis OWCP

[High_Profits]

UPDATED April 21st $OWCP 1 Page PDF to Download and Share
http://tinyurl.com/lnyuzoq

Follow $OWCP on Twitter
https://twitter.com/OWCPharma

Like OWCP on Facebook
https://www.facebook.com/OWCpharma/

$OWCP - Updated Website
Videos and Corporate Presentations
Http://www.owcpharma.com/newsroom-photos/

April 5th 2017 - OWC Pharmaceutical Research Corp Releases P[color=red]romising Preliminary Results [70%] From Efficacy Tests [/color]of its Topical Cream
https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-135700435.html

OWCP JPEG Image to Download to your smartphone and share
http://tinyurl.com/z29oxku

OWCP Current SEC Filings and News
https://www.otcmarkets.com/stock/OWCP/filings

OWCP #OWCP $OWCP

[High_Profits]

$OWCP NEWS - OWC Engages CFN Media Group for Upcoming MATERIAL Developments

June 19th 2017

https://finance.yahoo.com/news/owc-pharmaceuticals-engages-cfn-media-110000267.html

OWC Pharmaceuticals Engages CFN Media to Cultivate New Investor Audience & Communicate with Existing Shareholders

SEATTLE, WA--(Marketwired - Jun 19, 2017) - CFN Media Group ("CFN Media", "CannabisFN"), the leading agency and digital media network dedicated to the North American cannabis industry, today announced that OWC Pharmaceutical Research Corp. ( OTCQB : OWCP ) has engaged CFN Media to conduct a 2-month investor and market visibility program beginning on June 15, 2017.

"We are excited to be working with OWC Pharmaceutical Research once again," said Frank Lane, President of CFN Media. "The Israel-based company has made tremendous strides in developing its clinical programs, including its topical cannabinoid-based psoriasis cream that could provide much-needed relief to millions of sufferers worldwide."

"We are very excited to cooperate, again, with CFN Media," said Mordechai Bignitz, Chairman and CEO of OWC Pharmaceutical Research Corp. "In the near future OWC will report developments that we believe are material. CFN has proven themselves as a reliable and professional media outlet with exceptional editorial skills. Together with their video interviews we will have the best channel to convey our message to the investment community."

CFN Media will leverage its extensive reach and presence with mainstream and cannabis-focused investors and media across North America to elevate OWC Pharmaceutical Research Corp.'s brand and attract high-quality long-term investors.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to the worldwide cannabis industry, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and publicity. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

The company launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

About OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.

OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/

[High_Profits]

OWCP Related - https://www.facebook.com/IntivaBiopharma/

[High_Profits]

OWCP NEWS OUT - June 27th 2017

https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-announces-110000230.html

[High_Profits]

Looking forward to hearing from our new Chairman and see where he can take OWCP

http://www.owcpharma.com/our-leadership-team/

Dr. Stanley Hirsch – Chairman

Dr. Hirsch has extensive executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.

Dr. Hirsch served as Chairman of the Board of Directors of Foamix Pharmaceuticals Ltd., since 2016, and has also Group CEO of FuturaGene Limited and its predecessor company, FuturaGene Plc., since 2007.

Dr. Hirsch holds a D. Phil (1982) in Cell Biology and Immunolgy from Oxford University, UK. His educational experience also includes a B.Sc. degree with honors in Medical Biochemistry from the University of Capetown, South Africa (1979) among other academic honors and awards from Oxford University and University of Capetown